TP53 and breast cancer: In conclusion, our results have demonstrated that the encapsulation of an ATM inhibitor in a mitochondriotropic nanocarrier has the capacity to suppress doxorubicin resistance in breast cancer mammospheres independently of the cells’ p53 status.